vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v19i4S.2142vsp-2445Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEСовременные представления о возможностях вторичной профилактики «атопического марша» у детей с атопическим дерматитомModern Outlooks on «Atopic March» Secondary Prevention Capabilities in Children with Atopic Dermatitishttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич, доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей, профессор кафедры дерматовенерологии и косметологии ЦГМА, профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова, заведующий отделом детской дерматологии НИИ педиатрии и охраны здоровья детей ЦКБ РАН

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1

m_nn2001@mail.ruhttps://orcid.org/0000-0002-0081-0981Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.https://orcid.org/0000-0001-9777-0156ИвановР. А.IvanovRoman A.https://orcid.org/0000-0002-8232-8936ФёдоровД. В.FedorovDmitri V.https://orcid.org/0000-0002-4107-4642АмбарчянЭ. Т.AmbarchianEduard T.ЕпишевР. В.SavelovaAlena A.https://orcid.org/0000-0002-6034-8231МатерикинА. И.EpishevRoman V.https://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.MaterikinAlexander I.https://orcid.org/0000-0001-6884-5171СавеловаА. А.OpryatinLeonid A.Национальный медицинский исследовательский центр здоровья детей Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академия Управления делами Президента РФ; НИИ педиатрии и охраны здоровья детей ЦКБ РАН;РоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy of Department of Presidential Affairs; Research Institute of Pediatrics and Children’s Health in «Central Clinical Hospital of the Russian Academy of Sciences»Russian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАН; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical UniversityRussian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian FederationНациональный медицинский исследовательский центр здоровья детейRussian FederationCentral State Medical Academy of Department of Presidential AffairsRussian FederationЦентральная государственная медицинская академия Управления делами Президента РФРоссияNational Medical Research Center of Children’s HealthRussian Federation202002092020196514519Copyright © Мурашкин Н.Н., Намазова-Баранова Л.С., Иванов Р.А., Фёдоров Д.В., Амбарчян Э.Т., Епишев Р.В., Материкин А.И., Опрятин Л.А., Савелова А.А., 20202020Мурашкин Н.Н., Намазова-Баранова Л.С., Иванов Р.А., Фёдоров Д.В., Амбарчян Э.Т., Епишев Р.В., Материкин А.И., Опрятин Л.А., Савелова А.А.Murashkin N.N., Namazova-Baranova L.S., Ivanov R.A., Fedorov D.V., Ambarchian E.T., Savelova A.A., Epishev R.V., Materikin A.I., Opryatin L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2445

Атопический дерматит (АтД) является одним из самых распространенных воспалительных заболеваний детского возраста и первым звеном поэтапного развития аллергических заболеваний — «атопического марша». Формирование сенсибилизации на фоне неконтролируемого течения АтД ассоциировано с высоким риском развития серьезных аллергических патологий, увеличением степени тяжести течения болезни и снижением качества жизни пациентов. В связи с этим при тяжелом АтД у детей с ранним развитием заболевания необходимо добиться быстрого купирования воспалительного процесса. В статье рассмотрены современные терапевтические подходы к контролю заболевания у детей.

Atopic dermatitis (AD) is one of the most common inflammatory diseases of childhood, and it is the first one in gradual development of allergic diseases, also known as «atopic march». Sensitization establishment during the AD uncontrolled course is associated with the high risk of developing of serious allergic pathologies, increase in the severity of the disease course, and patients’ quality of life reduction. Thereby, it is crucial to achieve quick jugulation of the inflammatory process in case of severe AD with early onset of disease. This article shows modern therapeutic approaches to disease control in children.

атопический дерматитатопический маршсенсибилизациядетипроактивная терапияметилпреднизолона ацепонатdermatitisatopic marchsensibilizationchildrenproactive therapymethylprednisolone aceponateСтатья опубликована при поддержке компании LEO Pharma.The article has been funded by LEO PharmaReferencesMaliyar K, Sibbald C, Pope E, Gary Sibbald R. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538–550. doi: 10.1097/01.asw.0000547414.38888.8d.Maliyar K, Sibbald C, Pope E, Gary Sibbald R. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538–550. doi: 10.1097/01.asw.0000547414.38888.8d.Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35–39. doi: 10.1016/s0190-9622(94)70004-4.Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35–39. doi: 10.1016/s0190-9622(94)70004-4.Kowalska-Oledzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126–128. doi: 10.1080/21556660.2019.1619570.Kowalska-Oledzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126–128. doi: 10.1080/21556660.2019.1619570.Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010;30:269–280. doi: 10.1016/j.iac.2010.06.003.Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010;30:269–280. doi: 10.1016/j.iac.2010.06.003.Круглова Л.С., Генслер Е.М. Атопический дерматит: новые горизонты терапии // Медицинский Алфавит. Дерматология. — 2019. — Т. 1. — № 7(382). — С. 29–32. doi: 10.33667/2078-5631-2019-1-7(382)-29-32.Kruglova LS, Gensler EM. Atopic dermatitis: new horizons of therapy. Medical Alphabet. Dermatology. 2019;1(7):29–32. (In Russ). doi: 10.33667/2078-5631-2019-1-7(382)-29-32.Zheng T, Yu J, Oh MH, Zhu Z. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. Allergy Asthma Immunol Res. 2011;3(2):67–73. doi: 10.4168/aair.2011.3.2.67.Zheng T, Yu J, Oh MH, Zhu Z. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. Allergy Asthma Immunol Res. 2011;3(2):67–73. doi: 10.4168/aair.2011.3.2.67.Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner’s guide. Br J Dermatol. 2019; 181(5):895–906. doi: 10.1111/bjd.17766.Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner’s guide. Br J Dermatol. 2019; 181(5):895–906. doi: 10.1111/bjd.17766.Aw M, Penn J, Gauvreau GM, et al. Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020;181(1):1–10. doi: 10.1159/000502958.Aw M, Penn J, Gauvreau GM, et al. Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020;181(1):1–10. doi: 10.1159/000502958.Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi: 10.1016/S0140-6736(15)00149-X.Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi: 10.1016/S0140-6736(15)00149-X.Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27. doi: 10.1111/all.12268.Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27. doi: 10.1111/all.12268.Loh W, Tang M. The Epidemiology of Food Allergy in the Global Context. Int J Environ Res Public Health. 2018;15(9):2043. doi: 10.3390/ijerph15092043.Loh W, Tang M. The Epidemiology of Food Allergy in the Global Context. Int J Environ Res Public Health. 2018;15(9):2043. doi: 10.3390/ijerph15092043.Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(8537): 733–743. doi: 10.1016/S0140-6736(06)69283-0.Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(8537): 733–743. doi: 10.1016/S0140-6736(06)69283-0.Bantz SK, Zhu Z., Zheng T, et al. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. J Clin Cell Immunol. 2014;5(2):202. doi: 10.4172/2155-9899.1000202.Bantz SK, Zhu Z., Zheng T, et al. The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. J Clin Cell Immunol. 2014;5(2):202. doi: 10.4172/2155-9899.1000202.Lowe AJ, Carlin JB, Bennett CM, et al. Do boys do the atopic march while girls dawdle? J Allergy Clin Immunol. 2008;121(5): 1190–1195. doi: 10.1016/j.jaci.2008.01.034.Lowe AJ, Carlin JB, Bennett CM, et al. Do boys do the atopic march while girls dawdle? J Allergy Clin Immunol. 2008;121(5): 1190–1195. doi: 10.1016/j.jaci.2008.01.034.Knudsen TB, Thomsen SF, Nolte H, Backer V. A populationbased clinical study of allergic and non-allergic asthma. J Asthma. 2009;46(1):91–94. doi: 10.1080/02770900802524657.Knudsen TB, Thomsen SF, Nolte H, Backer V. A populationbased clinical study of allergic and non-allergic asthma. J Asthma. 2009;46(1):91–94. doi: 10.1080/02770900802524657.Leynaert B, Neukirch C, Kony S, et al. Association between asthma and rhinitis according to atopic sensitization in a populationbased study. J Allergy Clin Immunol. 2004;113(1):86–93. doi: 10.1016/j.jaci.2003.10.010.Leynaert B, Neukirch C, Kony S, et al. Association between asthma and rhinitis according to atopic sensitization in a populationbased study. J Allergy Clin Immunol. 2004;113(1):86–93. doi: 10.1016/j.jaci.2003.10.010.Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a populationbased study: HealthNuts age 4-year follow-up. J Allergy Clin Immunol. 2017;140(1):145–153.e8. doi: 10.1016/j.jaci.2017.02.019.Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a populationbased study: HealthNuts age 4-year follow-up. J Allergy Clin Immunol. 2017;140(1):145–153.e8. doi: 10.1016/j.jaci.2017.02.019.Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2): 131–137. doi: 10.1016/j.anai.2017.10.037.Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2): 131–137. doi: 10.1016/j.anai.2017.10.037.Belgrave DCM, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748. doi: 10.1371/journal.pmed.1001748.Belgrave DCM, Granell R, Simpson A, et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 2014;11(10):e1001748. doi: 10.1371/journal.pmed.1001748.Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”. J Allergy Clin Immunol. 2019;143(3):894–913. doi: 10.1016/j.jaci.2019.01.003.Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”. J Allergy Clin Immunol. 2019;143(3):894–913. doi: 10.1016/j.jaci.2019.01.003.Wisniewski JA, Agrawal R, Minnicozzi S, et al. Sensitization to food and inhalant allergens in relation to age and wheeze among children with atopic dermatitis. Clin Exp Allergy. 2013;43(10): 1160–1170. doi: 10.1111/cea.12169.Wisniewski JA, Agrawal R, Minnicozzi S, et al. Sensitization to food and inhalant allergens in relation to age and wheeze among children with atopic dermatitis. Clin Exp Allergy. 2013;43(10): 1160–1170. doi: 10.1111/cea.12169.Romeo MJ, Agrawal R, Pomes A, Woodfolk J. A molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease. J Allergy Clin Immunol. 2014;133(4):952–960. doi: 10.1016/j.jaci.2013.08.006.Romeo MJ, Agrawal R, Pomes A, Woodfolk J. A molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease. J Allergy Clin Immunol. 2014;133(4):952–960. doi: 10.1016/j.jaci.2013.08.006.Kelleher MM, Dunn-Galvin A, Gray C, et al. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016;137(4):1111–1116.e8. doi: 10.1016/j.jaci.2015.12.1312.Kelleher MM, Dunn-Galvin A, Gray C, et al. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016;137(4):1111–1116.e8. doi: 10.1016/j.jaci.2015.12.1312.Flohr C, England K, Radulovic S, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163(6):1333–1336. doi: 10.1111/j.1365-2133.2010.10068.x.Flohr C, England K, Radulovic S, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol. 2010;163(6):1333–1336. doi: 10.1111/j.1365-2133.2010.10068.x.Brough HA, Simpson A, Makinson K, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-offunction mutations. J Allergy Clin Immunol. 2014;134(4):867–875. e1. doi: 10.1016/j.jaci.2014.08.011.Brough HA, Simpson A, Makinson K, et al. Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-offunction mutations. J Allergy Clin Immunol. 2014;134(4):867–875. e1. doi: 10.1016/j.jaci.2014.08.011.McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280–291. doi: 10.1016/j.jaci.2012.12.668.McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280–291. doi: 10.1016/j.jaci.2012.12.668.Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373–384. doi: 10.1038/ni.1863.Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373–384. doi: 10.1038/ni.1863.Hradetzky S, Werfel T, Rosner LM. Autoallergy in atopic dermatitis. Allergo J Int. 2015;24(1):16–22. doi: 10.1007/s40629-015-0037-5.Hradetzky S, Werfel T, Rosner LM. Autoallergy in atopic dermatitis. Allergo J Int. 2015;24(1):16–22. doi: 10.1007/s40629-015-0037-5.Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43(1):29–40. doi: 10.1016/j.immuni.2015.07.007.Hammad H, Lambrecht BN. Barrier epithelial cells and the control of type 2 immunity. Immunity. 2015;43(1):29–40. doi: 10.1016/j.immuni.2015.07.007.Han H, Roan F, Ziegler SF, et al. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278(1):116–130. doi: 10.1111/imr.12546.Han H, Roan F, Ziegler SF, et al. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278(1):116–130. doi: 10.1111/imr.12546.Van der Pouw Kraan TC, Van der Zee JS, Boeije LC, et al. The role of IL-13 in IgE synthesis by allergic asthma patients. Clin Exp Immunol. 1998;111(1):129–135. doi: 10.1046/j.1365-2249.1998.00471.x.Van der Pouw Kraan TC, Van der Zee JS, Boeije LC, et al. The role of IL-13 in IgE synthesis by allergic asthma patients. Clin Exp Immunol. 1998;111(1):129–135. doi: 10.1046/j.1365-2249.1998.00471.x.Naclerio RM. Allergic rhinitis. N Engl J Med. 1991;325(12): 860–869. doi: 10.1056/NEJM199109193251206.Naclerio RM. Allergic rhinitis. N Engl J Med. 1991;325(12): 860–869. doi: 10.1056/NEJM199109193251206.Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004.Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004.Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7(5):e1000067. doi: 10.1371/journal.pbio.1000067.Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7(5):e1000067. doi: 10.1371/journal.pbio.1000067.Totte JEE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016; 175(4):687–695. doi: 10.1111/bjd.14566.Totte JEE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016; 175(4):687–695. doi: 10.1111/bjd.14566.Hata TR, Kotol P, Boguniewicz M, et al. History of eczema herpeticum is associated with the inability to induce human betadefensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol. 2010;163(3):659–661. doi: 10.1111/j.1365-2133.2010.09892.x.Hata TR, Kotol P, Boguniewicz M, et al. History of eczema herpeticum is associated with the inability to induce human betadefensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol. 2010;163(3):659–661. doi: 10.1111/j.1365-2133.2010.09892.x.Cepelak I, Dodig S, Pavic I, et al. Filaggrin and atopic march. Biochem Med. 2019;29(2):020501. doi: 10.11613/BM.2019.020501.Cepelak I, Dodig S, Pavic I, et al. Filaggrin and atopic march. Biochem Med. 2019;29(2):020501. doi: 10.11613/BM.2019.020501.Левина Ю.Г., Намазова-Баранова Л.С., Эфендиева К.Е. и др. Применение местных глюкокортикостероидов в лечении дерматитов у детей // Вопросы современной педиатрии. — 2019. — Т. 18. — № 5. — С. 380–385. doi: 10.15690/vsp.v18i5.2063.Levina YG, Namazova-Baranova LS, Efendiyeva KE, et al. Local Glucocorticoids in Treatment of Children with Dermatitis. Voprosy sovremennoi pediatrii — Current Pediatrics. 2019;18(5):380–385. (In Russ). doi: 10.15690/vsp.v18i5.2063.Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии // Вопросы современной педиатрии. — 2016. — Т. 15. — № 3. — С. 279–294. doi: 10.15690/vsp.v15i3.1566.Namazova-Baranova LS, Baranov AA, Kubanova AA, et al. Atopic Dermatitis in Children: Current Clinical Guidelines for Diagnosis and Therapy. Voprosy sovremennoi pediatrii — Current Pediatrics. 2016;15(3):279–294. (In Russ). doi: 10.15690/vsp.v15i3.1566.Torrelo A. Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol. 2017;56(6):691–697. doi: 10.1111/ijd.13485.Torrelo A. Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol. 2017;56(6):691–697. doi: 10.1111/ijd.13485.Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(3):251–258. doi: 10.1111/j.1468-3083.2010.03789.x.Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(3):251–258. doi: 10.1111/j.1468-3083.2010.03789.x.Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(5):508–515. doi: 10.1111/j.1468-3083.2010.03942.x.Blume-Peytavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(5):508–515. doi: 10.1111/j.1468-3083.2010.03942.x.Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders — a clinical update. Int J Clin Pract. 2006;60(1):85–92. doi: 10.1111/j.1368-5031.2005.00754.x.Ruzicka T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders — a clinical update. Int J Clin Pract. 2006;60(1):85–92. doi: 10.1111/j.1368-5031.2005.00754.x.Zaumseil R, Fuhrmann H, Kecskes A, et al. Methylprednisolone aceponate (Advantan) — an effective topical corticoid therapy with few side effects. In: Macher E, Kolde G, Brocker EB, eds. Jahrbuch der Dermatologie 1992/93. Zulpich, Germany: Blermann Verlag; 1993. S. 247–263.Zaumseil R, Fuhrmann H, Kecskes A, et al. Methylprednisolone aceponate (Advantan) — an effective topical corticoid therapy with few side effects. In: Macher E, Kolde G, Brocker EB, eds. Jahrbuch der Dermatologie 1992/93. Zulpich, Germany: Blermann Verlag; 1993. S. 247–263.Zentel HJ, Toepert M. Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 1994;3(Suppl. 1):S32–S38. doi: 10.1111/j.1468-083.1994.tb01061.x.Zentel HJ, Toepert M. Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 1994;3(Suppl. 1):S32–S38. doi: 10.1111/j.1468-083.1994.tb01061.x.Haria M, Balfour JA. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. Clin Immunother. 1995;3:241–253. doi: 10.1007/BF03259059.Haria M, Balfour JA. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. Clin Immunother. 1995;3:241–253. doi: 10.1007/BF03259059.Hoffmann K, Auer T, Stucker M, et al. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol. 1998;10(2):137–142.Hoffmann K, Auer T, Stucker M, et al. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol. 1998;10(2):137–142.Nawata H, Okabe T, Yanase T, et al. Mechanism of action and resistance to glucocorticoid and selective glucocorticoid receptor modulator to overcome glucocorticoid-related adverse effects. Clin Exp Allergy Rev. 2008;8(2):53–56. doi: 10.1111/j.1472-9733.2008.00137.xNawata H, Okabe T, Yanase T, et al. Mechanism of action and resistance to glucocorticoid and selective glucocorticoid receptor modulator to overcome glucocorticoid-related adverse effects. Clin Exp Allergy Rev. 2008;8(2):53–56. doi: 10.1111/j.1472-9733.2008.00137.xNewton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol. 2007;72(4):799–809. doi: 10.1124/mol.107.038794.Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol. 2007;72(4):799–809. doi: 10.1124/mol.107.038794.Mensing H, Lorenz B. Experience with Methylprednisolone Aceponate (MPA) in patients suffering from acute and chronic eczema — Is Results of a large observational study. Z Hautkr. 1998;73(5):281–285.Mensing H, Lorenz B. Experience with Methylprednisolone Aceponate (MPA) in patients suffering from acute and chronic eczema — Is Results of a large observational study. Z Hautkr. 1998;73(5):281–285.Niedner N, Zaumseil R-P. Advantan® Milk/Cream/Ointment in Children with Atopic Eczema and other Dermatoses — An Obser vational Study in 558 Children. Aktuelle Derm. 2004;30(6): 200–203. doi: 10.1055/s-2004-814472.Niedner N, Zaumseil R-P. Advantan® Milk/Cream/Ointment in Children with Atopic Eczema and other Dermatoses — An Obser vational Study in 558 Children. Aktuelle Derm. 2004;30(6): 200–203. doi: 10.1055/s-2004-814472.Peserico A, Stadtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801–807. doi: 10.1111/j.1365-2133.2008.08436.x.Peserico A, Stadtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801–807. doi: 10.1111/j.1365-2133.2008.08436.x.Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184–189. doi: 10.1111/j.1398-9995.2006.01269.x.Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184–189. doi: 10.1111/j.1398-9995.2006.01269.x.Ponte LG, Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2012;26(Suppl 6):9–13. doi: 10.1111/j.1468-3083.2012.04711.x.Ponte LG, Ebert U. Frontiers of rapid itch relief: a review of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2012;26(Suppl 6):9–13. doi: 10.1111/j.1468-3083.2012.04711.x.Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155(4):680–687. doi: 10.1111/j.1365-2133.2006.07410.x.Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155(4):680–687. doi: 10.1111/j.1365-2133.2006.07410.x.

The authors declare that there are no conflicts of interest present.